Feed HEPA
HE
Hepion Pharmaceuticals, Inc. HEPA · OTC
$0.10 +5.50% (+$0.01)
Summary
37 / 100 · Bulios Score
Valuation 100Growth 0Profitability -Quality 0Debt 69Stability 19
What speaks for it
- It has no debt and holds $1.63M in cash.
What to watch
- It passes only 1 of the 9 points of the Piotroski financial health test.
- The price moves much more than the market (beta 1.75).
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapIs it growing?
It is shrinkingRevenue (USD)
20212022202320242025
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $3.19M.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $1.63M
Debt $0.00
Free cash flow over 12 months -$1.59M
It has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 1
- Hold 2
- Sell 0
Today's price within the analysts' price targets
Today's price $0.1 Average target $70
$0.1 $70
The average target of $70 is 67,468% above today's price. 33% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.